By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL
In last’s year’s manufacturing outlook we delved into biopharma’s manufacturing capacity crunch. While lack of manufacturing capacity remains a challenge for the industry, the future of biopharma manufacturing has never looked so bright, and there is a variety of reasons why. For starters, when it comes to innovation in manufacturing, biopharma companies continue to push the envelope. Want proof? Take a quick review of the ISPE Facility of the Year Awards (FOYA), an annual program recognizing state-of-the-art projects by biopharma manufacturers. There you’ll see some old standbys (e.g., Abbott, Bristol-Myers Squibb, and Lilly) being recognized for operational excellence (OPEX), facility integration, and process innovation, but you’ll also encounter some lesser-known names. For example, Kalbio Global Medika’s young team (average age of 24) received an honorable mention for its 40,000-square-foot biotechnology manufacturing build in Jakarta, Indonesia. Nephron Pharmaceuticals Corp., another honorable mention, is a woman-owned business that also happens to be the world’s largest blow-fill-seal manufacturer.